Microvillus inclusion disease (MVID) is a cause of chronic watery diarrhea that is attributed to a lack of nutrient absorption in the gastrointestinal tract in newborns. The disease can lead to ...

Rare disease indications are the sole focus of Napo Therapeutics, the corporation established by Jaguar in Italy in 2021, with an initial focus on short bowel syndrome Jaguar to take the lead on ...

FRANKLIN SQUARE, Long Island (WABC) -- A family from Long Island is racing against the clock to find a cure for their son, who suffers from a rare genetic disease. Three-year-old Thomas Kevin Onorato ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion ...

MVID, a rare congenital diarrheal disorder (CDD) condition, is a life-threatening autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from ...

Intestinal microvilli, finger-like protrusions on the cell surface, are packed with the motor protein myosin-1a. This myosin was thought to serve a purely structural role, but now Vanderbilt cell ...

In mice, deletion of the Rab8 protein disrupts organized molecular distribution to membranes of intestinal epithelial cells. Death by starvation follows, exactly as it does in humans with microvillus ...

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 20, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, in support of a possible ...

SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite ...